Abstract
Polycystic ovarian disease (PCOD) is a common endocrine disorder. Majority of young females are affected. Insulin resistance along with dysfunction of hypothalamo pituitory adrenal axis is a key etiological factor in development of all manifestations of PCOD. They present with irregular menses, infertility, obesity, hirsutism, acanthosis Nigricans etc. MI(MI),an insulin sensitizer is widely accepted treatment modality. Data suggests variable responses to MI. So we aimed to study efficacy of MI in PCOS. Here 32 cases are recruited those diagnosed by using Rotterdam’s criteria .BMI, menstrual irregularity, infertility, hirsutism, acanthosis Nigricans, acne were common presenting features. Hormonal & biochemical profile was studied S.LH (Luteinizing Hormone), FSH (Follicle stimulating hormone), Serum. Prolactin levels, Serum Insulin levels were studied. Weight loss, menstrual regularity, LH/FSH Ratio, HOMA Index was studied initially & compared all parameters after 3 months of treatment. In our study BMI mean was 26.71, after MI treatment it became 25.6.Differences of all parameters before & after MI suggests, there is significant reduction in BMI & LH/FSH ratio. Other parameters are not affected by MI. It suggests MI has been effective in reducing BMI & LH/ FSH ratio significantly. But there was no change in HOMA index. So MI can be good supportive treatment option in PCOD.
The present study gives us idea about efficacy of MI treatment in PCOD cases & will be useful in patient treatment schedules.
Keywords- PCOD (Polycystic ovarian Disease), Hyperinsulinemia, Myoinositol (MI), Body Mass Index (BMI), LH/FSH-Luteinizing hormone & Follicle stimulating hormone ratio, HOMA index-Homeostatic model assessment.
References
1. Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol. Jun 2010;162(6):1093-9.
2. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–993.
3. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. ClinEndocrinol (Oxf). Aug 2006;65(2):137-45.
4. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347–354.
5. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13:105–110.
6. Minozzi M, D’Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008;17:579–582.
7. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.N Engl J Med 1999;340:1314–1320.
8. Unfer V, Carlomagno G, Dante G, Facchinetti F Gynecol Endocrinol. 2012 Feb 1-7. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
9. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
10. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle Metformin in polycystic ovary syndrome: systematic review and meta-analysis
11. Jonathan M Lord, Ingrid H K Flight, Robert J Norman, professor3 BMJ 2003; 327 doi: http://dx.doi.org/10.1136/bmj.327.7421.951 (Published 23 October 2003) Cite this as: BMJ 2003;327:951 intervention and metformin. Diabetes. 2005;54:2404-2414.
12. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositoladministration positively affects hyperinsulinemia and hormonalparameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–144.
Corresponding Author
Dr Jayshree Awalekar
M.D, Professor, Dept of Medicine
Bharati Vidyapeeth Deemed University Medical College & Hospital, Sangli
Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Mobile: 09422045082 Fax No. : 0233-2601201
DOI: http://dx.doi.org/10.18535/jmscr/v3i10.31
